UFPT UFP TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 914156 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.6%
TTM net income YoY14.0%
TTM EPS YoY13.7%
Revenue 3-yr CAGR18.6%
Net income 3-yr CAGR22.4%
Margins
Gross margin28.9%
Operating margin15.5%
Net margin11.8%
FCF margin—
EBITDA margin18.5%
Returns
ROE17.2%
ROA11.5%
ROIC (approx.)15.0%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets28.8%
Debt / equity0.20x
Current ratio2.98x
Interest coverage14.64x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio0.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $172.43M | $173.96M | $154.20M | $148.91M | $154.56M | $151.18M | $148.15M | $144.07M |
| Cost of revenue | $121.67M | $123.05M | $109.84M | $106.95M | $111.81M | $107.63M | $106.00M | $102.01M |
| Gross profit | $50.76M | $50.92M | $44.36M | $41.97M | $42.75M | $43.54M | $42.15M | $42.06M |
| SG&A expense | $23.15M | $22.75M | $21.02M | $20.96M | $19.07M | $18.68M | $18.73M | $18.62M |
| Operating income | $27.61M | $28.10M | $23.37M | $21.50M | $23.38M | $24.33M | $23.13M | $22.26M |
| Interest expense | $1.49M | $1.71M | $1.74M | $1.93M | $2.39M | $2.67M | $2.81M | $3.38M |
| Pretax income | $26.12M | $26.43M | $21.61M | $19.54M | $21.06M | $21.63M | $20.28M | $19.10M |
| Income tax | $5.50M | $5.58M | $4.11M | $1.98M | $4.68M | $4.45M | $3.10M | $2.72M |
| Net income | $20.62M | $20.85M | $17.50M | $17.57M | $16.38M | $17.18M | $17.18M | $16.38M |
| EBITDA | $30.13M | $30.59M | $25.79M | $33.71M | $20.97M | $29.05M | $25.37M | $31.12M |
| EPS (basic) | 2.66 | 2.69 | 2.27 | 2.28 | 2.12 | 2.23 | 2.24 | 2.13 |
| EPS (diluted) | 2.64 | 2.68 | 2.24 | 2.25 | 2.11 | 2.21 | 2.21 | 2.10 |
| Weighted avg. shares (diluted) | 7.81M | 7.79M | 7.80M | — | 7.78M | 7.77M | 7.78M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $20.62M | $9.04M | $19.98M | $20.30M | $18.23M | $14.89M | $14.03M | $13.45M |
| Receivables | $97.15M | $113.25M | $98.57M | $82.91M | $85.18M | $84.93M | $93.78M | $84.68M |
| Inventory | $98.15M | $100.09M | $93.98M | $86.86M | $86.15M | $85.20M | $89.84M | $87.54M |
| Current assets | $230.64M | $234.89M | $224.11M | $201.00M | $197.97M | $191.39M | $205.89M | $194.94M |
| PP&E, net | $78.58M | $76.92M | $78.40M | $79.11M | $77.54M | $73.92M | $71.51M | $70.56M |
| Goodwill | $198.88M | $196.44M | $196.65M | $197.40M | $197.30M | $192.97M | $190.56M | $189.66M |
| Intangibles | $136.19M | $135.25M | $137.86M | $140.85M | $143.26M | $141.97M | $141.97M | $144.25M |
| Total assets | $682.63M | $681.91M | $674.68M | $655.08M | $652.82M | $634.66M | $642.64M | $629.00M |
| Current liabilities | $77.36M | $78.30M | $77.01M | $74.86M | $82.23M | $69.19M | $79.87M | $76.30M |
| Short-term debt | $12.50M | $12.50M | $12.50M | $12.50M | $12.50M | $12.50M | $12.50M | $12.50M |
| Long-term debt | $83.50M | $104.81M | $125.11M | $122.95M | $133.62M | $151.12M | $163.62M | $176.88M |
| Total debt | $96.00M | $117.31M | $137.61M | $135.46M | $146.12M | $163.62M | $176.12M | $189.38M |
| Total liabilities | $196.92M | $219.48M | $235.81M | $231.20M | $248.91M | $249.17M | $281.97M | $286.24M |
| Shareholders' equity | $485.71M | $462.43M | $438.88M | $423.88M | $403.91M | $385.49M | $360.67M | $342.76M |
| Net debt | $75.38M | $108.26M | $117.63M | $115.15M | $127.89M | $148.73M | $162.10M | $175.93M |
| Shares outstanding | 7.75M | 7.75M | 7.74M | 7.71M | 7.71M | — | 7.71M | 7.68M |
| Cash flow statement | ||||||||
| Operating cash flow | $38.54M | $15.61M | $3.20M | $16.84M | $35.92M | $25.33M | $13.81M | $24.42M |
| Capital expenditure | — | — | — | — | — | $2.86M | $2.82M | $3.01M |
| Free cash flow | — | — | — | — | — | $22.47M | $10.99M | $21.42M |
| Investing cash flow | -$10.87M | -$1.10M | -$1.69M | -$3.86M | -$15.27M | -$5.65M | -$2.82M | -$3.88M |
| Financing cash flow | -$16.06M | -$25.36M | -$1.62M | -$10.88M | -$17.49M | -$19.08M | -$10.70M | -$22.72M |
| Depreciation & amortization | $2.52M | $2.49M | $2.42M | $12.20M | -$2.40M | $4.72M | $2.25M | $8.86M |
| Stock-based compensation | $2.79M | $3.22M | $2.73M | $2.40M | $1.96M | $2.29M | $2.21M | $2.06M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.